Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy

Phase 2

Completed

• Conditions: Photosensitive Epilepsy
• Interventions: Drug: BGG492; Drug: Placebo

• Registration Number: NCT00784212
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

This study will evaluate the efficacy of BGG492 in reducing the sensitivity to flashing lights of patients with photosensitive epilepsy, using EEG as a readout.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-10
• Study First Submitted: 2008-10-31
• Study First Submitted QC: 2008-10-31
• Study First Posted: 2008-11-02
• Primary Completion: 2010-09
• Study Completion: 2010-09
• Status Verified: 2016-09
• Last Update Submitted: 2016-09-21
• Last Update Posted: 2016-09-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 13

Inclusion Criteria

• diagnosis of photosensitive epilepsy

Exclusion Criteria

• inconsistent photoparoxysmal response when stimulated by photic stimulation

Other protocol-defined inclusion/exclusion criteria may apply.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cohort II	BGG492	-
Cohort III	Placebo	-
Cohort 1	BGG492	-

Primary Outcome Measures

Name	Time	Method
Outcome Measure: Photoparoxysmal response (PPR) and standardized photoparoxysmal response (SPR) determined by EEG on all treatment days.	Days 1, 2 and 3

Secondary Outcome Measures

Name	Time	Method
Outcome Measure: Safety and tolerability of BGG492 in patients with photosensitive epilepsy	From Day 1 until Day 33 after treatment start.

Trial Locations

Locations (1)

Novartis Investigator Site; 🇩🇪 Radeberg, Germany